A Randomized, Double-blind, Multicenter Study to Explore the Effect of GED-0301 on Endoscopic and Clinical Outcomes in Subjects With Active Crohn's Disease

Trial Profile

A Randomized, Double-blind, Multicenter Study to Explore the Effect of GED-0301 on Endoscopic and Clinical Outcomes in Subjects With Active Crohn's Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Mongersen (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 28 Oct 2016 According to a Celgene Corporation media release, data from this trial is expected at the Advances in Inflammatory Bowel Diseases (AIBD) meeting in December.
    • 16 Oct 2016 According to a Celgene Corporation media release, data from this trial will be presented at the United European Gastroenterology Week (UEGW).
    • 16 Oct 2016 Results published in the Celgene Corporation media release Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top